Published in Hum Vaccin Immunother on November 01, 2012
Plasma-activated air mediates plasmid DNA delivery in vivo. Mol Ther Methods Clin Dev (2016) 0.75
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res (2006) 2.34
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Nonviral gene delivery: what we know and what is next. AAPS J (2007) 2.04
In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta (1991) 2.00
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther (2006) 1.84
IL-28 and IL-29: newcomers to the interferon family. Biochimie (2007) 1.81
IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res (2006) 1.77
Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood (2006) 1.76
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Antitumor activity of IFN-lambda in murine tumor models. J Immunol (2006) 1.63
Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev (2004) 1.48
IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev (2010) 1.45
IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther (2002) 1.36
IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol (2007) 1.35
Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther (2010) 1.35
Electroporation for targeted gene transfer. Expert Opin Drug Deliv (2005) 1.27
Novel electrode designs for electrochemotherapy. Biochim Biophys Acta (1997) 1.15
IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol (2003) 1.14
Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res (2010) 1.10
Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther (2006) 1.02
Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci (2004) 1.01
DNA drugs come of age. Sci Am (2010) 0.99
Evaluation of a novel non-penetrating electrode for use in DNA vaccination. PLoS One (2011) 0.96
An epoch-making application of discharge plasma phenomenon to gene-transfer. Biotechnol Bioeng (2005) 0.92
Plasma facilitated delivery of DNA to skin. Biotechnol Bioeng (2009) 0.90
Enhancement of antigen specific humoral immune responses after delivery of a DNA plasmid based vaccine through a contact-independent helium plasma. Vaccine (2010) 0.87
Characterization of plasma mediated molecular delivery to cells in vitro. Int J Pharm (2010) 0.87
A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects. Clin Dev Immunol (2011) 0.87
Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci (2011) 0.87
New anticancer immunotherapies. Anticancer Res (2012) 0.87
IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial. Methods Mol Biol (2008) 0.85
Non-contact helium-based plasma for delivery of DNA vaccines. Enhancement of humoral and cellular immune responses. Hum Vaccin Immunother (2012) 0.84
Liposome-mediated IL-28 and IL-29 expression in A549 cells and anti-viral effect of IL-28 and IL-29 on WISH cells. Acta Pharmacol Sin (2006) 0.82
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis (2004) 1.73
Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther (2009) 1.44
T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS (2002) 1.27
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine (2005) 1.09
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. Hum Gene Ther (2010) 1.02
Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci (2007) 1.00
Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci (2004) 0.97
Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. J Infect Dis (2003) 0.93
Serosurveillance of eastern equine encephalitis virus in amphibians and reptiles from Alabama, USA. Am J Trop Med Hyg (2012) 0.91
Plasma facilitated delivery of DNA to skin. Biotechnol Bioeng (2009) 0.90
Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine (2005) 0.90
Enhancement of antigen specific humoral immune responses after delivery of a DNA plasmid based vaccine through a contact-independent helium plasma. Vaccine (2010) 0.87
Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther (2006) 0.87
Characterization of plasma mediated molecular delivery to cells in vitro. Int J Pharm (2010) 0.87
Comparison of electrically mediated and liposome-complexed plasmid DNA delivery to the skin. Genet Vaccines Ther (2008) 0.85
Non-contact helium-based plasma for delivery of DNA vaccines. Enhancement of humoral and cellular immune responses. Hum Vaccin Immunother (2012) 0.84
Effect of electrochemotherapy on muscle and skin. Technol Cancer Res Treat (2002) 0.84
Phage-displayed mimotopes recognizing a biologically active anti-HIV-1 gp120 murine monoclonal antibody. J Acquir Immune Defic Syndr (2002) 0.83
Vaccine development against HIV-1: current perspectives and future directions. Immunol Res (2002) 0.83
Enhancement of anti-melanoma activity of a plasmid expressing HIV-1 Vpr delivered through in vivo electroporation. Cancer Biol Ther (2007) 0.82
Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations. Hum Vaccin Immunother (2015) 0.79
Analysis of the potential for HIV-1 Vpr as an anti-cancer agent. Curr HIV Res (2009) 0.78
Anti-cancer activity of the HIV accessory molecule viral protein R (Vpr): Delivery as a DNA expression plasmid or biologically active peptides. Vaccine (2010) 0.78
Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37. DNA Cell Biol (2004) 0.78
Electric field enhanced plasmid delivery to liver hepatocellular carcinomas. Technol Cancer Res Treat (2002) 0.77
Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine. Viral Immunol (2013) 0.77
HIV-1 Vpr: enhancing sensitivity of tumors to apoptosis. Curr Drug Deliv (2004) 0.77
Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfection with human T-cell leukemia virus type I and HIV-1. J Acquir Immune Defic Syndr (2003) 0.77
Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. J Neuroimmune Pharmacol (2010) 0.76
Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease. Hum Vaccin Immunother (2014) 0.75
DNA vaccines 2010: a gumbo of accomplishment and excitement in New Orleans. Vaccine (2011) 0.75
Fluorometric assay to compensate for non-viable cells during electroporation. J Fluoresc (2014) 0.75
Feasibility study for focusing electric fields to mediate in vitro drug and gene delivery. Conf Proc IEEE Eng Med Biol Soc (2006) 0.75